Genmab — Juni 2024
-
Det er nu tid til at øge beholdningen af Genmab. I andet halvår af 2024 vil vi få svar på mange afgørende forsøg, og hvis dataene er som forventet og indikeret af Genmab, bør kursen ligge pænt over 3000 før jul. Juni er traditionelt en god måned at investere i Genmab. Hold grundigt øje med teknisk analyse (TA) signalerne. Historisk set har køb af Genmab-aktier tæt på junilavpunktet været et af de bedste tidspunkter at købe Genmab på.
-
Godmorgen
-
Genmab får løftet kursmål med 6 pct. hos Truist https://proinvestor.com/investornyt/1168323/genmab-far-loftet-kursmal-med-6-pct-hos-truist
-
ASCO24: Sanofi's Sarclisa gains ground on Darzalex's frontline myeloma turf https://firstwordpharma.com/story/5863350
-
Subcutaneous Epcoritamab Demonstrated Efficacy Among Patients With R/R DLBCL and FL Treated in the Outpatient Setting
Results from phase 2 EPCORE NHL-6 https://www.hmpgloballearningnetwork.com/site/onc/conference-coverage/subcutaneous-epcoritamab-demonstrated-efficacy-among-patients-rr-dlbcl -
Genmab-topchef om nye data: ”Uden fortilfælde” https://medwatch.dk/Medicinal___Biotek/article17161592.ece
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind